ImmunoRNases combine tumor targeting by antibodies with the cytotoxic action of ribonucleases from the RNase A superfamily. This study investigated for the first time all catalytic active human RNase A family members (1 to 8) as effector components of antibody fusion proteins. ImmunoRNase fusion proteins were constructed using the CD30-specific bivalent recombinant scFv-Fc antibody SH313-B5. Production of the resulting entirely human immunoRNases 1 to 8 was done in mammalian cells by secretion of active forms. The immunoRNases mediated CD30-specific cell binding and showed ribonucleolytic activity. Interestingly, immunoRNases 1 and 2 were active in the presence of up to 5-/20-fold molar excess of the pancreatic RNase inhibitor (RI), which is supposed to efficiently inhibit all human RNase A activity. ImmunoRNases 3, 4, 6 and 7 were only inhibited by several fold molar excess of RI, whereas immunoRNases 5 and 8 were already completely inactive at equimolar RI concentrations. Compared to free RNases, activity and RI sensitivity were not significantly changed by antibody fusion or dimerisation. ImmunoRNase3 and 5 mediated tumor growth inhibition at low nanomolar concentrations. Anti-tumor activity was antigen-specific and did not show any correlation with ribonucleolytic activity or RI sensitivity.
AleksandrowiczJ., Intracutaneous ribonuclease in chronic myelocytic leukemia, Lancet272 (1958), 420–422.
2.
AtkinsP. and De PaulaJ., Physical Chemistry, Oxford University Press 8. Edition, (2006), 810.
3.
BarrabésS.Pagès-PonsL.RadcliffeC.TabarésG.FortE.RoyleL.HarveyD.MoennerM.DwekR.RuddP.De LlorensR. and PeracaulaR., Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer, Glycobiology17 (2007), 388–400.
4.
BoixE.WuY.VasandaniV.M.SaxenaS.K.ArdeltW.LadnerJ. and YouleR.J., Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity, J Mol Biol257 (1996), 992–1007.
5.
BöllB.BorchmannP. and EngertA., Experimentelle Therapie des Hodgkin-Lymphoms, Onkologe16 (2010), 48–54.
6.
BoschM.BenitoA.RiboM.PuigT.BeaumelleB. and VilanovaM., A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity, Biochemistry43 (2004), 2167–2177.
7.
BraschossS.HirschB.DübelS.SteinH. and DürkopH., New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo, Leuk Lymphoma48 (2007), 1179–1186.
8.
CabritaL.GilisD.RobertsonA.DehouckY.RoomanM. and BottomleyS., Enhancing the stability and solubility of TEV protease using in silico design, Protein Sci.16 (2007), 2360–2367.
9.
CarterJ.ZhangJ.DangT.L.HasegawaH.ChengJ.D.GiananI.O’NeillJ.W.WolfsonM.SiuS.QuS.MeiningerD.KimH.DelaneyJ. and MehlinC., Fusion partners can increase the expression of recombinant interleukins via transient transfection in 2936E cells, Protein Sci19 (2010), 357–362.
10.
De LorenzoC.ArcielloA.CozzolinoR.PalmerD.B.LaccettiP.PiccoliR. and D’AlessioG., A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas, Cancer Res64 (2004), 4870–4874.
11.
De LorenzoC.Di MaltaC.CaliG.TroiseF.NitschL. and D’AlessioG., Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent, FEBS Lett581 (2007), 296–300.
12.
delCardayreS.B.RiboM.YokelE.M.QuirkD.J.RutterW.J. and RainesR.T., Engineering ribonuclease A: production, purification and characterization of wild-type enzyme and mutants at Gln11, Protein Eng8 (1995), 261–273.
13.
EngertA.EichenauerD.DreylingM. and GroupE.G.W., Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol21 (2010), 168–171.
14.
FaliniB.PileriS.PizzoloG.DurkopH.FlenghiL.StirpeF.MartelliM.F. and SteinH., CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy, Blood85 (1995), 1–14.
15.
FangL.JiaK.Z.TangY.L.MaD.Y.YuM. and HuaZ.C., An improved strategy for high-level production of TEV protease in Escherichia coli and its purification and characterization, Protein Expr Purif51 (2007), 102–109.
16.
FischerP.NachevaE.MasonD.Y.SherringtonP.D.HoyleC.HayhoeF.G. and KarpasA., A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin’s lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene, Blood72 (1988), 234–240.
17.
FoyilK.V. and BartlettN.L., Anti-CD30 Antibodies for Hodgkin lymphoma, Curr Hematol Malig Rep5 (2010), 140–147.
GovindanS. and GoldenbergD., New antibody conjugates in cancer therapy, ScientificWorldJournal12 (2010), 2070–2089.
20.
GuptaR.JungE. and BrunakS., Prediction of N-glycosylation sites in human proteins, NetNGlyc 1.0 Server; http://www.cbs.dtu.dk/services/NetNGlyc/ In preparation (2004).
21.
HarderJ. and SchroderJ.M., RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin, J Biol Chem277 (2002), 46779–46784.
22.
HenrichsT.MikhalevaN.ConzC.DeuerlingE.BoydD.ZelaznyA.BibiE.BanN. and EhrmannM., Target-directed proteolysis at the ribosome, Proc Natl Acad Sci U S A102 (2005), 4246–4251.
23.
HetzelC.BachranC.FischerR.FuchsH.BarthS. and StockerM., Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells, J Immunother31 (2008), 370–376.
24.
HofsteengeJ.VicentiniA. and ZelenkoO., Ribonuclease 4, an evolutionarily highly conserved member of the superfamily, Cell Mol Life Sci54 (1998), 804–810.
25.
HollowayD.E.ChavaliG.B.HaresM.C.BakerM.D.SubbaraoG.V.ShapiroR. and AcharyaK.R., Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38–41, Biochemistry43 (2004), 1230–1241.
26.
HorieR. and WatanabeT., CD30: expression and function in health and disease, Semin Immunol10 (1998), 457–470.
27.
HuG.RiordanJ. and ValleeB., A putative angiogenin receptor in angiogenin-responsive human endothelial cells, Proc Natl Acad Sci U S A94 (1997), 2204–2209.
28.
HübingerG.MüllerE.ScheffrahnI.SchneiderC.HildtE.SingerB.SiggI.GrafJ. and BergmannL., CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299, Oncogene20 (2001), 590–598.
29.
JägerV.BüssowK.WagnerA.WeberS.HustM.FrenzelA. and SchirrmannT., High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells, BMC Biotechnology13 (2013).
30.
JonaA. and YounesA., Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma, Blood Rev.24 (2010), 233–238.
31.
KelemenB.R.KlinkT.A.BehlkeM.A.EubanksS.R.LelandP.A. and RainesR.T., Hypersensitive substrate for ribonucleases, Nucleic Acids Res27 (1999), 3696–3701.
32.
KlinkT.A.VicentiniA.M.HofsteengeJ. and RainesR.T., High-level soluble production and characterization of porcine ribonuclease inhibitor, Protein Expr Purif22 (2001), 174–179.
33.
KraussJ.ArndtM.A.VuB.K.NewtonD.L.SeeberS. and RybakS.M., Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein, Biochem Biophys Res Commun331 (2005), 595–602.
34.
KüppersR.YahalomJ. and JostingA., Advances in biology, diagnostics, and treatment of Hodgkin’s disease, Biol Blood Marrow Transplant12 (2006), 66–76.
35.
LelandP.A.SchultzL.W.KimB.M. and RainesR.T., Ribonuclease A variants with potent cytotoxic activity, Proc Natl Acad Sci U S A95 (1998), 10407–10412.
36.
MathewM. and VermaR.S., Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy, Cancer Sci100 (2009), 1359–1365.
37.
MenzelC.SchirrmannT.KonthurZ.JostockT. and DubelS., Human antibody RNase fusion protein targeting CD30+ lymphomas, Blood111 (2008), 3830–3837.
38.
MikulskiS.CostanziJ.VogelzangN.McCachrenS.TaubR.ChunH.MittelmanA.PanellaT.PuccioC.FineR. and ShogenK., Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma, J Clin Oncol.1;20 (2002), 274–281.
39.
NagataS.OndaM.NumataY.SantoraK.BeersR.KreitmanR.J. and PastanI., Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments, Clin Cancer Res8 (2002), 2345–2355.
40.
NewtonD.StockwinL. and RybakS., Anti-CD22 Onconase: preparation and characterization, Methods Mol Biol.525 (2009), 425–443.
41.
NewtonD.L.NichollsP.J.RybakS.M. and YouleR.J., Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv, J Biol Chem269 (1994), 26739–26745.
42.
NicholsN.M. and YueD., Ribonucleases, Curr Protoc Mol BiolChapter 3 (2008).
43.
OrtínM., Immunotherapy of hematological malignancies: what is new? Ann Oncol.16 (2005), ii53–62.
44.
Palanca-WesselsM. and PressO., Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas, Cancer Immunol Immunother116 (2010), 1126–1133.
45.
PohlS.C.SchwarzS.FrenzelA. and SchirrmannT., A Cassette Vector System for the Rapid Cloning and Production of Bispecific Tetravalent Antibodies, Antibodies1 (2012), 19–38.
46.
RainesR.T. and RibonucleaseA., Chem. Rev. (1998), 1045–1065.
47.
RehmanM.DeyP.HassanM.AhmadF. and BatraJ., Functional role of glutamine 28 and arginine 39 in double stranded RNA cleavage by human pancreatic ribonuclease, PLoS One6 (2011), e17159.
48.
RiboM.delCardayreS.B.RainesR.T.de LlorensR. and CuchilloC.M., Production of human pancreatic ribonuclease in Saccharomyces cerevisiae and Escherichia coli, Protein Expr Purif7 (1996), 253–261.
49.
RosenbergH. and DomachowskeJ., Eosinophils, ribonucleases and host defense: solving the puzzle, Immunol Res.20 (1999), 261–274.
50.
RosenbergH.F., Recombinant Human Eosinophil Cationic Protein, Biological Chemistry270 (1995), 7876–7881.
51.
RosenbergH.F., The eosinophil ribonucleases, Cell Mol Life Sci54 (1998), 795–803.
52.
RosenbergH.F., Eosinophil-derived Neurotoxin/RNase 2: connecting the past, the present and the future, Curr Pharm Biotechnol.9(3) (2008), 135–140.
53.
RybakS.ArndtM.SchirrmannT.DübelS. and KraussJ., Ribonucleases and immunoRNases as anticancer drugs, Curr Pharm Des.15 (2009), 2665–2675.
54.
RybakS.M.ArndtM.A.SchirrmannT.DubelS. and KraussJ., Ribonucleases and ImmunoRNases as Anticancer Drugs, Current Pharmaceutical Design15 (2009), 2665–2675.
55.
SchifferS.HansenH.Hehmann-TittG.HuhnM.FischerR.BarthS. and ThepenT., Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model, Blood Cancer J3 (2013).
56.
SchifferS.LetzianS.JostE.MladenovR.HristodorovD.HuhnM.FischerR.BarthS. and ThepenT., Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells, Cancer Lett.341 (2013), 178–185.
57.
SchirrmannT.FrenzelA.LindenL.Stelte-LudwigB.WilludaJ.HarrengaA.DübelS.Müller-TiemannB. and TrautweinM., Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform, MAbs6 (2014), 367–380.
SchirrmannT.SteinwandM.WezlerX.Ten HaafA.TurM. and BarthS., CD30 as a therapeutic target for lymphoma, BioDrugs28 (2014), 181–209.
60.
SchütteM.ThullierP.PelatT.WezlerX.RosenstockP.HinzD.KirschM.HasenbergM.FrankR.SchirrmannT.GunzerM.HustM. and DübelS., Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus., PLoS One4 (2009), e6625.
61.
SharkeyR.M. and GoldenbergD.M., Targeted therapy of cancer: new prospects for antibodies and immunoconjugates, CA Cancer J Clin56 (2006), 226–243.
62.
ShihY.WuH.HuS.WangT. and WangA., Self-cleavage of fusion protein in vivo using TEV protease to yield native protein, Protein Sci.14 (2005), 936–941.
63.
SorrentinoS., Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types, Cell Mol Life Sci54 (1998), 785–794.
64.
SorrentinoS., The eight human “canonical” ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins, FEBS Lett584 (2010), 2194–2200.
65.
SorrentinoS. and LibonatiM., Human pancreatic-type and nonpancreatic-type ribonucleases: a direct side-by-side comparison of their catalytic properties, Arch Biochem Biophys312 (1994), 340–348.
66.
StahnkeB.ThepenT.StöckerM.RosinkeR.JostE.FischerR.TurM. and BarthS., Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes, Mol Cancer Ther.7 (2008), 2924–2932.
StrydomD.J., The angiogenins, Cell Mol Life Sci54 (1998), 811–824.
69.
SuzukiM.SaxenaS.BoixE.PrillR.VasandaniV.LadnerJ.SungC. and YouleR., Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction, Nat Biotechnol17 (1999), 265–270.
70.
Tello-MontoliuA.PatelJ.V. and LipG.Y., Angiogenin: a review of the pathophysiology and potential clinical applications, J Thromb Haemost4 (2006), 1864–1874.
71.
TerzyanS.S.PeracaulaR.de LlorensR.TsushimaY.YamadaH.SenoM.Gomis-RuthF.X. and CollM., The three-dimensional structure of human RNase 4, unliganded and complexed with d(Up), reveals the basis for its uridine selectivity, J Mol Biol285 (1999), 205–214.
72.
TurM.NeefI.JägerG.TeubnerA.StöckerM.MelmerG. and BarthS., Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy, Curr Pharm Des.15 (2009), 2693–2699.
73.
TurM.NeefI.JostE.GalmO.JägerG.StöckerM.RibbertM.OsiekaR.KlingeU. and BarthS., Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells, J Immunother.32 (2009), 431–441.
74.
TurcotteR.F.LavisL.D. and RainesR.T., Onconase cytotoxicity relies on the distribution of its positive charge, Febs J276 (2009), 3846–3857.
75.
VengeP. and BystromJ., Eosinophil cationic protein (ECP), Int J Biochem Cell Biol30 (1998), 433–437.
76.
WangZ.MathiasA.StavrouS. and NevilleD.J., A new yeast display vector permitting free scFv amino termini can augment ligand binding affinities, Protein Eng Des Sel.18 (2005), 337–343.
77.
WatanabeM.OgawaY.ItohK.KoiwaT.KadinM.WatanabeT. and OkayasuI., Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma, Laboratory Investigation88 (2008), 48–57.
78.
WezlerX.HustM.HelmsingS.SchirrmannT. and DübelS., Human antibodies targeting CD30+ lymphomas, Hum Antibodies21 (2012), 13–28.
79.
WuY.MikulskiS.M.ArdeltW.RybakS.M. and YouleR.J., A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity, J Biol Chem268 (1993), 10686–10693.
80.
ZeweM.RybakS.M.DubelS.CoyJ.F.WelschofM.NewtonD.L. and LittleM., Cloning and cytotoxicity of a human pancreatic RNase immunofusion, Immunotechnology3 (1997), 127–136.
81.
ZhangJ.DyerK.D. and RosenbergH.F., RNase 8, a novel RNase A superfamily ribonuclease expressed uniquely in placenta, Nucleic Acids Res30 (2002), 1169–1175.
82.
ZhangJ.DyerK.D. and RosenbergH.F., Human RNase 7: a new cationic ribonuclease of the RNase A superfamily, Nucleic Acids Res31 (2003), 602–607.
